The phase 3b STRENGTH study reported that a single dose of OAV101IT was well tolerated in treatment-experienced patients with spinal muscular atrophy, with motor function stabilizing over 52 weeks.:
Source: Neurology Read More
Intrathecal Onasemnogene Abeparvovec Demonstrates Favorable Safety and Motor Function Stabilization in Treatment-Experienced Patients With SMA
Related Posts
<![CDATA[Once-Daily Alixorexton Improves Cognition,
Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1
Study]]>
<![CDATA[Once-Daily Alixorexton Improves Cognition, Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1 Study]]>
